GSK gaining rights to Hutchmed’s KRAS/EFGR drug in $1.295B deal

GSK plc is moving further into antibody-drug conjugates, taking ex-China rights to Hutchmed Ltd.’s HMPL-A830 in a deal worth up to $1.295 billion, plus royalties. Of that, GSK is paying $110 million up front for the preclinical asset, which features a dual mode of action, linking an anti-epidermal…